Inspire Medical Systems, Inc. Announces Full Integration of Inspire Therapy into German DRG Reimbursement System to Begin in 2021
MINNEAPOLIS, Minnesota -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), today announced that Inspire therapy will be integrated into the German hospital reimbursement system (“G-DRG”), effective January 1, 2021. Germany’s Institute for the Hospital Remuneration System (“InEK”) recently published the list of treatment methods, including Inspire therapy, to be included in the regular DRG catalog.
Since January 2016, Germany’s reimbursement for the Inspire procedure has been provided through the NUB process for new diagnostic and treatment procedures. The NUB process allows hospitals to submit requests for reimbursement of “new and innovative treatment methods” that have not yet obtained a G-DRG code. The NUB process requires hospitals to submit applications annually to obtain approval to perform the Inspire procedure. While Inspire therapy has received the top NUB1 rating for each of the last five years, this remains an interim step in
establishing formal reimbursement in Germany.
“We are very excited to announce the InEK decision, as it will secure long-term reimbursement for Inspire therapy in Germany, which we expect will improve access for patients with untreated OSA in that country. The decision to include Inspire in the DRG catalog demonstrates that our procedure has become part of routine clinical practice in Germany,” commented Inspire President and CEO Timothy P. Herbert. “Our focus remains on ensuring high-quality patient care with trained centers in Germany.”
Andreas Henke, Inspire’s Senior Vice President for Europe, added: “The decision of the InEK is based on the excellent work of the surgeons and hospitals in Germany who have treated patients with Inspire therapy over the past five years. Their experience with Inspire therapy during this time has shown that a new treatment procedure can be introduced safely and effectively from clinical development to routine care. In fact, the data generated to date from commercial Inspire therapy cases in Germany has demonstrated that our technology has delivered treatment outcomes that are the same or better than the results achieved in controlled studies.”
Related news
-
Professional Old Age Home Care Services in Australia
JK Home Care is delighted to extend its range of professional home care services in Australia. Transforming home care solutions, the specialized team of qualified experts at JK Home Care offer world-class therapeutic supports, specialized supported employment, specialized positive behavior support, participation in the community, innovative community participation, home modifications and more aligned to the patient’s requirement. JK Home Care was born out of a desire to care and give back to the community....
-
Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy
Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care Three patients had complete responses, with another patient still under evaluation Tel Aviv, Israel and Basel, Switzerland, 12 August 2021 – Sheba Medical Center at Tel Hashomer, the largest hospital in the...
-
Femasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeed
First in Class Insemination Treatment for Infertility LOCAL Pivotal Trial to Enroll Up to 792 Patients Across 20 U.S. Centers Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on transforming women`s healthcare, today announced the initiation and first patient treated in a pivotal trial evaluating FemaSeed, a first in class, localized directional insemination product candidate for infertility. “For more than 20 years, current approaches to infertility treatment have been limited during the...
-
Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimicsTM vaccine, EO2463, in non-Hodgkin lymphoma
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine • EO2463 combines four microbiome-peptides of B lymphocytes-specific lineage markers designed to induce the full depletion of malignant B lymphocytes ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, announces that the first patient was dosed in a Phase 1/2 clinical trial (‘SIDNEY’)...
-
Med Tech Outlook: Top Medical Ventilator Solution Providers 2021
Accurate breath analysis is key for diagnosis and assessment of pulmonary illnesses. Breath analysis is an important evaluation tool to support respiratory therapists and pulmonologists in the diagnosis and treatment of varying respiratory illnesses. Unfortunately, moisture is an impediment to successful breath analysis. Moisture in breath samples can adversely impact the accuracy of breath analysis and damage devices. As such, respiratory device providers seek robust solutions that reduce moisture from breath...
Customer comments
No comments were found for Inspire Medical Systems, Inc. Announces Full Integration of Inspire Therapy into German DRG Reimbursement System to Begin in 2021. Be the first to comment!